Inotek is a leader in the development of innovative drugs to address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead product candidate trabodenoson has demonstrated clinically meaningful efficacy and tolerability in late-stage glaucoma clinical trials. The Company believes trabodenoson will be a first-in-class breakthrough treatment that can be used alone or combined with other IOP-lowering products because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy eyes to maintain normal IOP.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/27/13 | $21,000,000 |
Horizon Technology Finance Pitango Venture Capital Rho Ventures | undisclosed | |
| 09/27/13 | $7,000,000 | Venture Debt |
Horizon Technology Finance | undisclosed |
